ATAI Life Sciences N.V. Common Shares
Symbol: ATAI (NASDAQ)
5.96
▼ (-7.24%) -0.465
Company Description:
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Key Stats
- Today's Open: $5.925
- Today's High: $5.955
- Today's Low: $5.856
- Today's Volume: 16.31K
- Yesterday Close: $6.42
- Yesterday High: $6.75
- Yesterday Low: $6.28
- Yesterday Volume: 10.32M
- Last Min Volume: 245
- Last Min High: $5.955
- Last Min Low: $5.955
- Last Min VWAP: $5.955
Company Profile
- Name: ATAI Life Sciences N.V. Common Shares
- Website: https://www.atai.life
- Listed Date: 2021-06-18
- Location: AMSTELVEEN,
- Market Status: Active
- CIK Number: 0001840904
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.50B
- Round Lot: 100
- Outstanding Shares: 233.78M
- Asset Type: CS
RECENT FILINGS FOR ATAI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-21 | 8-K | View |
| 2025-10-20 | SCHEDULE 13D/A | View |
| 2025-10-20 | 8-K | View |
| 2025-10-17 | 424B5 | View |
| 2025-10-16 | 424B5 | View |
| 2025-10-16 | DEFA14A | View |
| 2025-10-16 | 8-K | View |
| 2025-10-10 | DEFA14A | View |
| 2025-10-10 | 8-K | View |
| 2025-10-03 | 4 | View |
| 2025-10-03 | 3 | View |
| 2025-10-02 | 4 | View |
| 2025-09-29 | S-3ASR | View |
| 2025-09-29 | DEFA14A | View |
| 2025-09-29 | 8-K | View |
| 2025-09-24 | DEFM14A | View |
| 2025-09-23 | DEFA14A | View |
| 2025-09-23 | 8-K | View |
| 2025-08-18 | SCHEDULE 13D/A | View |
| 2025-08-18 | 4 | View |
Latest News on ATAI